We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
From Dec 2023 to Jun 2024
By P.R. Venkat
AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former's efforts to grow its cell therapies business.
The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell's last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.
The deal's total value would reach $1.2 billion when combined with potential contingent value payments.
The acquisition will help grow AstraZeneca's pipeline of cell therapies for potential treatment of cancer and autoimmune diseases.
The transaction is expected to close in the first quarter of next year, AstraZeneca said. It will also acquire the cash, cash equivalents and short-term investments on Gracell's balance sheet, which totaled $234.1 million as of the end of September.
Following the deal, Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the U.S.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
December 26, 2023 02:50 ET (07:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
